Winst gevend schreef op 16 december 2019 23:24:
Voor 20 miljoen gekocht van Novartis met extra betalingen richting Novartis.
Deze GAP-filler is een verlies maker en Novartis dankt de Goden dat zij
dit brok onkosten aan Pharming heeft gesleten voor veel geld.
If successful, the development of CDZ173 will have been slashed to less than half the industry norm of more than a decade. And Christ emphasizes that NIBR will move ahead although it doesn’t expect to make back its investment on trials for such a rare condition.
“All of our NIBR research has to be paid for, of course, but we have the freedom to explore indications that are not of commercial value to help people who are in desperate need of a medicine,” Christ says. “This is just the right thing to do.”
- it doesn’t expect to make back its investment
- are not of commercial value
En dat werd al verteld in 2015/2016
WAT EEN AFGANG.